REFERENCES
1. Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, et al. Seroprevalence
of parvovirus B19 in the German population. Epidemiol Infect. 2008 Nov;136(11):1564–75.
2. Weir E. Parvovirus B19 infection: fifth disease and more. CMAJ Can Med Assoc J
J Assoc Medicale Can. 2005 Mar 15;172(6):743.
3. Brodin-Sartorius A, Mekki Y, Bloquel B, Rabant M, Legendre C. [Parvovirus B19 infection
after kidney transplantation]. Nephrol Ther. 2012 Feb;8(1):5–12.
4. Waldman M, Kopp JB. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol CJASN.
2007 Jul;2 Suppl 1:S47-56.
5. Besse W, Mansour S, Jatwani K, Nast CC, Brewster UC. Collapsing glomerulopathy
in a young woman with APOL1 risk alleles following acute parvovirus B19 infection:
a case report investigation. BMC Nephrol. 2016 06;17(1):125.
6. Moudgil A, Nast CC, Bagga A, Wei L, Nurmamet A, Cohen AH, et al. Association of
parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int. 2001
Jun;59(6):2126–33.
7. Magro CM, Crowson AN, Dawood M, Nuovo GJ. Parvoviral infection of endothelial cells
and its possible role in vasculitis and autoimmune diseases. J Rheumatol. 2002 Jun;29(6):1227–35.
8. Nakazawa T, Tomosugi N, Sakamoto K, Asaka M, Yuri T, Ishikawa I, et al. Acute glomerulonephritis
after human parvovirus B19 infection. Am J Kidney Dis. 2000 Jun;35(6):e31.1-e31.8.
9. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002 Jul;15(3):485–505.
10. Aberham C, Pendl C, Gross P, Zerlauth G, Gessner M. A quantitative, internally
controlled real-time PCR Assay for the detection of parvovirus B19 DNA. J Virol Methods.
2001 Apr;92(2):183–91.
11. Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. Persistence
of human parvovirus B19 in human tissues. Pathol Biol (Paris). 2002 Jun;50(5):307–16.
12. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England
and Wales. J Med Microbiol. 1988 Feb;25(2):151–3.
13. Vyse AJ, Andrews NJ, Hesketh LM, Pebody R. The burden of parvovirus B19 infection
in women of childbearing age in England and Wales. Epidemiol Infect. 2007 Nov;135(8):1354–62.
14. Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific
prevalence of human parvovirus immunity in Victoria, Australia compared with other
parts of the world. Epidemiol Infect. 2000 Jun;124(3):449–57.
15. Parra D, Mekki Y, Durieu I, Broussolle C, Sève P. [Clinical and biological manifestations
in primary parvovirus B19 infection in immunocompetent adult: a retrospective study
of 26 cases]. Rev Med Interne. 2014 May;35(5):289–96.
16. Erdman DD, Usher MJ, Tsou C, Caul EO, Gary GW, Kajigaya S, et al. Human parvovirus
B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons
with erythema infectiosum. J Med Virol. 1991 Oct;35(2):110–5.
17. Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous
immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection:
a retrospective study of 10 patients and review of the literature. Clin Infect Dis
Off Publ Infect Dis Soc Am. 2013 Apr;56(7):968–77.
18. Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, et al. Neutralization
of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion (Paris).
2008 Jan;48(1):178–86.
19. Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, et al. Detection
of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent
assay. J Clin Microbiol. 1986 Oct;24(4):522–6.
20. Jensen IP, Vestergaard BF. Assessment of the specificity of a commercial human
parvovirus B19 IgM assay. Clin Diagn Virol. 1997 Feb;7(3):133–7.
21. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia Vasculitis.
Am J Med. 2015 Sep;128(9):950–5.
22. Chiche L, Grados A, Harlé J-R, Cacoub P. Mixed cryoglobulinemia: a role for parvovirus
b19 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010 Apr 1;50(7):1074–5.
23. Lazzerini PE, Cusi MG, Selvi E, Capecchi M, Moscadelli V, Migliacci N, et al.
Non-HCV-related cryoglobulinemic vasculitis and parvovirus-B19 infection. Jt Bone
Spine Rev Rhum. 2018 Jan;85(1):129–30.
24. Terrier B, Marie I, Lacraz A, Belenotti P, Bonnet F, Chiche L, et al. Non HCV-related
infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas
survey and systematic review of the literature. J Autoimmun. 2015 Dec;65:74–81.
25. Pugliese A, Beltramo T, Torre D, Roccatello D. Parvovirus B19 and immune disorders.
Cell Biochem Funct. 2007 Dec;25(6):639–41.
26. Hermann J, Demel U, Stünzner D, Daghofer E, Tilz G, Graninger W. Clinical interpretation
of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann
Rheum Dis. 2005 Apr;64(4):641–3.
27. von Landenberg P, Lehmann HW, Modrow S. Human parvovirus B19 infection and antiphospholipid
antibodies. Autoimmun Rev. 2007 Apr;6(5):278–85.
28. Barnett LA, Fujinami RS. Molecular mimicry: a mechanism for autoimmune injury.
FASEB J Off Publ Fed Am Soc Exp Biol. 1992 Feb 1;6(3):840–4.
29. Georges E, Rihova Z, Cmejla R, Decleire P-Y, Langen C. Parvovirus B19 induced
lupus-like syndrome with nephritis. Acta Clin Belg. 2016 Dec;71(6):423–5.
30. Sugimoto T, Tsuda A, Uzu T, Kashiwagi A. Emerging lupus-like manifestations in
acute parvovirus B19 infection. Clin Rheumatol. 2008 Jan;27(1):119–20.
31. Tanawattanacharoen S, Falk RJ, Jennette JC, Kopp JB. Parvovirus B19 DNA in kidney
tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis Off J
Natl Kidney Found. 2000 Jun;35(6):1166–74.
32. von Kietzell K, Pozzuto T, Heilbronn R, Grössl T, Fechner H, Weger S. Antibody-mediated
enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor
for complement factor C1q. J Virol. 2014 Jul;88(14):8102–15.
33. Takeda S, Takaeda C, Takazakura E, Haratake J. Renal involvement induced by human
parvovirus B19 infection. Nephron. 2001 Nov;89(3):280–5.